



#6

SEQUENCE LISTING

<110> Gish, Kurt C.
Mack, David H.
Afar, Daniel
Eos Biotechnology, Inc.

<120> Uses of PBH1 in the Diagnosis and Therapeutic Treatment
of Prostate Cancer

<130> 018501-005910US

<140> US 10/058,513

<141> 2002-01-24

<150> US 60/263,951

<151> 2001-01-24

<160> 42

<170> PatentIn Ver. 2.1

<210> 1

<211> 4225

<212> DNA

<213> Homo sapiens

<220>

<223> prostate cancer modulating protein (PCMP) PBH1

<220>

<221> CDS

<222> (43)..(4225)

<223> PBH1

<400> 1

```
gccagcttct acgctgcctt caggacacag acgtgcccaa tcatggcttc ttggtgcttg 60
attacagctc aagtctgggt caaaatgaag ggagatgtgg tgggcagccg cagccctcag 120
caacacaagc ggagcacagg aacacctcag ggtcttccag ttcccatctc agaaggctca 180
atgaaatcct tccttcctgt ccacaccatc gtgcttatca gggagaatgt gtgcaagtgt 240
ggctatgccc agagccagca catggaaggc acccagatca accaaagtga gaaatggaac 300
tacaagaaac acaccaagga atttcctacc gacgcctttg gggatattca gtttgagaca 360
ctggggaaga aagggaagta tatacgtctg tcctgcgaca cggacgcgga aatcctttac 420
gagctgctga cccagcactg gcacctgaaa acaccaacc tggtcatttc tgtgaccggg 480
ggcgccaaga acttcgccct gaagccgcgc atgcgcaaga tcttcagccg gtcctctac 540
atcgcgcagt ccaaagggtc ttggattctc acgggaggca cccattatgg cctgatgaag 600
tacatcgggg aggtggtgag agataacacc atcagcagga gttcagagga gaattattgt 660
gccattggca tagcagcttg gggcatggtc tccaaccggg acaccctcat caggaattgc 720
gatgctgagg gctatttttt agcccagtac cttatggatg acttcacaag agatccactg 780
tatatcctgg acaacaacca cacacatttg ctgctcgtgg acaatggctg tcatggacat 840
cccactgtcg aagcaaagct ccggaatcag ctagagaagt atatctctga gcgcactatt 900
caagattcca actatggttg caagatcccc attgtgtgtt ttgccaagg aggtggaaaa 960
gagactttga aagccatcaa tacctccatc aaaaataaaa ttcttgtgt ggtggtggaa 1020
ggctcggggc agatcgctga tgtgatcgct agcctggtgg aggtggagga tgccctgaca 1080
tcttctgccc tcaaggagaa gctggtgcgc tttttacccc gcacgggtgc ccggctgcct 1140
gaggaggaga ctgagagttg gatcaaattg ctcaaagaaa ttctcgaatg ttctcaccta 1200
ttaacagtta ttaaaatgga agaagctggg gatgaaattg tgagcaatgc catctcctac 1260
gctctataca aagccttcag caccagtga caagacaagg ataactggaa tgggcagctg 1320
aagcttctgc tggagtggaa ccagctggac ttagccaatg atgagatttt caccaatgac 1380
cgccgatggg agaagagcaa accgaggctc agagacacaa taatccaggt cacatggctg 1440
gaaaatggta gaatcaaggt tgagagcaaa gatgtgactg acggcaaagc ctcttctcat 1500
```

atgctggtgg	ttctcaagtc	tgctgacctt	caagaagtca	tgtttacggc	tctcataaag	1560
gacagaccca	agtttgtccg	cctctttctg	gagaatggct	tgaacctacg	gaagtttctc	1620
acccatgatg	tcctcactga	actcttctcc	aaccatttca	gcacgcttgt	gtaccggaat	1680
ctgcagatcg	ccaagaattc	ctataatgat	gccctcctca	cgtttgtctg	gaaactgggt	1740
gcgaacttcc	gaagaggctt	ccggaaggaa	gacagaaatg	gccgggacga	gatggacata	1800
gaactccacg	acgtgtctcc	tattactcgg	cacccctcgc	aagctctctt	catctgggcc	1860
attcttcaga	ataagaagga	actctccaaa	gtcatttggg	agcagaccag	gggctgcact	1920
ctggcagccc	tgggagccag	caagcttctg	aagactctgg	ccaaagtga	gaacgacatc	1980
aatgctgctg	gggagtccga	ggagctggct	aatgagtacg	agaccggggc	tgttgagctg	2040
ttcactgagt	gttacagcag	cgatgaagac	ttggcagaac	agctgctggg	ctattcctgt	2100
gaagcttggg	gtggaagcaa	ctgtctggag	ctggcggtgg	aggccacaga	ccagcatttc	2160
atcgcccagc	ctgggggtcca	ggaggggagg	gctgtgcccg	tcccatgctt	gcaaggatgc	2220
tgacgatgcc	cttatctctg	ggtccaggaa	gaaacctgtc	gacaagcaca	agaagctgct	2280
ttggtactat	gtggcggttct	tcacctcccc	cttcgtggtc	ttctcctgga	atgtggtctt	2340
ctacatcgcc	ttcctcctgc	tgtttgccta	cgtgctgctc	atggatttcc	attcgggtgcc	2400
acaccccccc	gagctggtcc	tgtactcgct	ggcttttgtc	ctcttctgtg	atgaagtga	2460
acagatggag	caggggggtg	cgctcgtgga	ggaggctcgg	gcagcacagg	agcccactga	2520
ggggggtggg	ggctcaggca	tggtgggctg	cagggtcccga	gccctgcccc	acgggaaggc	2580
agctacggcc	cgccccggtt	ccgctcacg	ccactccttc	cacacttccc	tgcaagctga	2640
gggtgccagc	tctggccttg	gccagcccag	aaaggggctc	ccacagtga	gcgggtgggt	2700
gaagggctcc	tcaagtgccg	ccaaagtggg	agcccaggca	gaggagggtg	cgagagcaag	2760
cgagggctgc	gaggactgcc	agcacgctgt	cacctctcag	aagcgtaagg	gactggctga	2820
tgtcttatca	cggactggga	acaactggga	cagtgtctgc	cccacaagtg	ggtggtacgt	2880
aaatgggggtg	aattattttta	ctgacctgtg	gaatgtgatg	gacacgctgg	ggcttttttta	2940
cttcatagca	ggaattgtat	ttcggtccca	ctcttcta	aaaagctctt	tgtattctgg	3000
acgagtcatt	ttctgtctgg	actacattat	tttactcta	agattgatcc	acatttttac	3060
tgtaagcaga	aacttaggac	ccaagattat	aatgctgcag	aggatgacga	gcattgagat	3120
gagctcatct	ggaagctcca	ttccaacact	gaggttcttt	gagtttgtgg	ttttaattca	3180
aagcatttct	gggacatcca	gtcatcatga	agtcatgcta	tctgatcgat	gtgttcttct	3240
tctgttctct	ctttgcggtg	tggtgggtgg	cctttgcgtg	gccaggcaag	ggatccttag	3300
gcagaatgag	cagcgctgga	ggtggatatt	ccgttcggtc	atctacgagc	cctacctggc	3360
catgttcggc	cagggtgcca	gtgacgtgga	tggtaccacg	tatgactttg	cccactgcac	3420
cttcaactggg	aatgagtcca	agccactgtg	tgtggagctg	gatgagcaca	acctgccccg	3480
gttccccgag	tggtatcacca	tccccctggt	gtgcatctac	atgttatcca	ccaacatcct	3540
gctgggtcaac	ctgctggctg	ccatgtttgg	gtgtgtagcc	ggtgggctag	ttcaggttct	3600
tgactttggg	acagaaaata	atgtgaaagt	gagtcaaaag	caaaagcaag	caagagagtt	3660
gactgcaaag	ccaaagtaca	ctctagcagc	cgctgggttc	aggagatgga	cctcagctgt	3720
cactgcatgt	ctccagccag	ctaggtgttt	gccaggga	ggacgccaag	ggcacaagat	3780
atcgctggag	atgcacaaa	ggaaaattgc	agaattctct	cagggaaca	accagatggc	3840
cactgggtgt	caaggagact	ttaagaacca	tctcagatgg	ggcggttaca	cggtgggcac	3900
cgtccaggag	aacaatgacc	aggtctggaa	gttccagagg	tacttctctg	tgaggagta	3960
ctgcagccgc	ctcaatatcc	ccttccccct	catcgtcttc	gcttacttct	acatgggtgg	4020
gaagaagtgc	ttcaagtgtt	gctgcaagga	gaaaaacatg	gagtcttctg	tctgctctgt	4080
ggaggcaggt	gaagatgctt	acaattatag	ggaacataag	gaaggctcaa	aagagctttt	4140
tgggagccag	tgtgccttga	tgctagtctt	tgctgccact	ctgattcgtt	gcctgtttta	4200
tttgaggggc	attggaaatg	cgtga				4225

<210> 2

<211> 1393

<212> PRT

<213> Homo sapiens

<220>

<223> prostate cancer modulating protein (PCMP) PBH1

<400> 2

Met Ala Ser Trp Cys Leu Ile Thr Ala Gln Val Trp Val Lys Met Lys

1

5

10

15

Gly	Asp	Val	Val	Gly	Ser	Arg	Ser	Pro	Gln	Gln	His	Lys	Arg	Ser	Thr	20	25	30
Gly	Thr	Pro	Gln	Gly	Leu	Pro	Val	Pro	Ile	Ser	Glu	Gly	Ser	Met	Lys	35	40	45
Ser	Phe	Leu	Pro	Val	His	Thr	Ile	Val	Leu	Ile	Arg	Glu	Asn	Val	Cys	50	55	60
Lys	Cys	Gly	Tyr	Ala	Gln	Ser	Gln	His	Met	Glu	Gly	Thr	Gln	Ile	Asn	65	70	75
Gln	Ser	Glu	Lys	Trp	Asn	Tyr	Lys	Lys	His	Thr	Lys	Glu	Phe	Pro	Thr	85	90	95
Asp	Ala	Phe	Gly	Asp	Ile	Gln	Phe	Glu	Thr	Leu	Gly	Lys	Lys	Gly	Lys	100	105	110
Tyr	Ile	Arg	Leu	Ser	Cys	Asp	Thr	Asp	Ala	Glu	Ile	Leu	Tyr	Glu	Leu	115	120	125
Leu	Thr	Gln	His	Trp	His	Leu	Lys	Thr	Pro	Asn	Leu	Val	Ile	Ser	Val	130	135	140
Thr	Gly	Gly	Ala	Lys	Asn	Phe	Ala	Leu	Lys	Pro	Arg	Met	Arg	Lys	Ile	145	150	155
Phe	Ser	Arg	Leu	Ile	Tyr	Ile	Ala	Gln	Ser	Lys	Gly	Ala	Trp	Ile	Leu	165	170	175
Thr	Gly	Gly	Thr	His	Tyr	Gly	Leu	Met	Lys	Tyr	Ile	Gly	Glu	Val	Val	180	185	190
Arg	Asp	Asn	Thr	Ile	Ser	Arg	Ser	Ser	Glu	Glu	Asn	Ile	Val	Ala	Ile	195	200	205
Gly	Ile	Ala	Ala	Trp	Gly	Met	Val	Ser	Asn	Arg	Asp	Thr	Leu	Ile	Arg	210	215	220
Asn	Cys	Asp	Ala	Glu	Gly	Tyr	Phe	Leu	Ala	Gln	Tyr	Leu	Met	Asp	Asp	225	230	235
Phe	Thr	Arg	Asp	Pro	Leu	Tyr	Ile	Leu	Asp	Asn	Asn	His	Thr	His	Leu	245	250	255
Leu	Leu	Val	Asp	Asn	Gly	Cys	His	Gly	His	Pro	Thr	Val	Glu	Ala	Lys	260	265	270
Leu	Arg	Asn	Gln	Leu	Glu	Lys	Tyr	Ile	Ser	Glu	Arg	Thr	Ile	Gln	Asp	275	280	285
Ser	Asn	Tyr	Gly	Gly	Lys	Ile	Pro	Ile	Val	Cys	Phe	Ala	Gln	Gly	Gly	290	295	300
Gly	Lys	Glu	Thr	Leu	Lys	Ala	Ile	Asn	Thr	Ser	Ile	Lys	Asn	Lys	Ile	305	310	315
Pro	Cys	Val	Val	Val	Glu	Gly	Ser	Gly	Gln	Ile	Ala	Asp	Val	Ile	Ala	325	330	335

Ser Leu Val Glu Val Glu Asp Ala Leu Thr Ser Ser Ala Val Lys Glu
 340 345 350
 Lys Leu Val Arg Phe Leu Pro Arg Thr Val Ser Arg Leu Pro Glu Glu
 355 360 365
 Glu Thr Glu Ser Trp Ile Lys Trp Leu Lys Glu Ile Leu Glu Cys Ser
 370 375 380
 His Leu Leu Thr Val Ile Lys Met Glu Glu Ala Gly Asp Glu Ile Val
 385 390 395 400
 Ser Asn Ala Ile Ser Tyr Ala Leu Tyr Lys Ala Phe Ser Thr Ser Glu
 405 410 415
 Gln Asp Lys Asp Asn Trp Asn Gly Gln Leu Lys Leu Leu Leu Glu Trp
 420 425 430
 Asn Gln Leu Asp Leu Ala Asn Asp Glu Ile Phe Thr Asn Asp Arg Arg
 435 440 445
 Trp Glu Lys Ser Lys Pro Arg Leu Arg Asp Thr Ile Ile Gln Val Thr
 450 455 460
 Trp Leu Glu Asn Gly Arg Ile Lys Val Glu Ser Lys Asp Val Thr Asp
 465 470 475 480
 Gly Lys Ala Ser Ser His Met Leu Val Val Leu Lys Ser Ala Asp Leu
 485 490 495
 Gln Glu Val Met Phe Thr Ala Leu Ile Lys Asp Arg Pro Lys Phe Val
 500 505 510
 Arg Leu Phe Leu Glu Asn Gly Leu Asn Leu Arg Lys Phe Leu Thr His
 515 520 525
 Asp Val Leu Thr Glu Leu Phe Ser Asn His Phe Ser Thr Leu Val Tyr
 530 535 540
 Arg Asn Leu Gln Ile Ala Lys Asn Ser Tyr Asn Asp Ala Leu Leu Thr
 545 550 555 560
 Phe Val Trp Lys Leu Val Ala Asn Phe Arg Arg Gly Phe Arg Lys Glu
 565 570 575
 Asp Arg Asn Gly Arg Asp Glu Met Asp Ile Glu Leu His Asp Val Ser
 580 585 590
 Pro Ile Thr Arg His Pro Leu Gln Ala Leu Phe Ile Trp Ala Ile Leu
 595 600 605
 Gln Asn Lys Lys Glu Leu Ser Lys Val Ile Trp Glu Gln Thr Arg Gly
 610 615 620
 Cys Thr Leu Ala Ala Leu Gly Ala Ser Lys Leu Leu Lys Thr Leu Ala
 625 630 635 640
 Lys Val Lys Asn Asp Ile Asn Ala Ala Gly Glu Ser Glu Glu Leu Ala
 645 650 655

Asn	Glu	Tyr	Glu	Thr	Arg	Ala	Val	Glu	Leu	Phe	Thr	Glu	Cys	Tyr	Ser	
			660					665					670			
Ser	Asp	Glu	Asp	Leu	Ala	Glu	Gln	Leu	Leu	Val	Tyr	Ser	Cys	Glu	Ala	
		675					680					685				
Trp	Gly	Gly	Ser	Asn	Cys	Leu	Glu	Leu	Ala	Val	Glu	Ala	Thr	Asp	Gln	
	690					695					700					
His	Phe	Ile	Ala	Gln	Pro	Gly	Val	Gln	Arg	Gly	Gly	Leu	Cys	Pro	Ser	
705					710					715					720	
His	Ala	Cys	Lys	Asp	Ala	Asp	Asp	Ala	Leu	Ile	Ser	Gly	Ser	Arg	Lys	
				725					730					735		
Lys	Pro	Val	Asp	Lys	His	Lys	Lys	Leu	Leu	Trp	Tyr	Tyr	Val	Ala	Phe	
			740					745					750			
Phe	Thr	Ser	Pro	Phe	Val	Val	Phe	Ser	Trp	Asn	Val	Val	Phe	Tyr	Ile	
		755					760					765				
Ala	Phe	Leu	Leu	Leu	Phe	Ala	Tyr	Val	Leu	Leu	Met	Asp	Phe	His	Ser	
	770					775					780					
Val	Pro	His	Pro	Pro	Glu	Leu	Val	Leu	Tyr	Ser	Leu	Val	Phe	Val	Leu	
785					790				795						800	
Phe	Cys	Asp	Glu	Val	Arg	Gln	Met	Glu	Gln	Gly	Val	Ala	Leu	Val	Glu	
				805					810					815		
Glu	Ala	Arg	Ala	Ala	Gln	Glu	Pro	Thr	Glu	Gly	Val	Gly	Gly	Ser	Gly	
			820					825					830			
Met	Val	Gly	Cys	Arg	Ser	Arg	Ala	Leu	Pro	His	Gly	Lys	Ala	Ala	Thr	
		835					840					845				
Ala	Arg	Pro	Gly	Ser	Arg	Ser	Arg	His	Ser	Phe	His	Thr	Ser	Leu	Gln	
	850					855					860					
Ala	Glu	Gly	Ala	Ser	Ser	Gly	Leu	Gly	Gln	Pro	Arg	Lys	Gly	Leu	Pro	
865					870					875					880	
Gln	Cys	Ser	Gly	Gly	Leu	Lys	Gly	Ser	Ser	Ser	Ala	Ala	Lys	Val	Gly	
				885					890					895		
Ala	Gln	Ala	Glu	Glu	Val	Pro	Arg	Ala	Ser	Glu	Gly	Cys	Glu	Asp	Cys	
			900					905					910			
Gln	His	Ala	Val	Thr	Ser	Gln	Lys	Arg	Lys	Gly	Leu	Ala	Asp	Val	Leu	
		915					920					925				
Ser	Arg	Thr	Gly	Asn	Asn	Trp	Asp	Ser	Val	Cys	Pro	Thr	Ser	Gly	Trp	
		930				935					940					
Tyr	Val	Asn	Gly	Val	Asn	Tyr	Phe	Thr	Asp	Leu	Trp	Asn	Val	Met	Asp	
945					950					955					960	
Thr	Leu	Gly	Leu	Phe	Tyr	Phe	Ile	Ala	Gly	Ile	Val	Phe	Arg	Leu	His	
				965					970					975		

Ser Ser Asn Lys Ser Ser Leu Tyr Ser Gly Arg Val Ile Phe Cys Leu
 980 985 990
 Asp Tyr Ile Ile Phe Thr Leu Arg Leu Ile His Ile Phe Thr Val Ser
 995 1000 1005
 Arg Asn Leu Gly Pro Lys Ile Ile Met Leu Gln Arg Met Thr Ser Ile
 1010 1015 1020
 Glu Met Ser Ser Ser Gly Ser Ser Ile Pro Thr Leu Arg Phe Phe Glu
 1025 1030 1035 1040
 Phe Val Val Leu Ile Gln Ser Ile Ser Gly Thr Ser Ser His His Glu
 1045 1050 1055
 Val Met Leu Ser Asp Arg Cys Val Leu Leu Pro Val Pro Leu Cys Gly
 1060 1065 1070
 Val Asp Gly Gly Leu Cys Val Ala Arg Gln Gly Ile Leu Arg Gln Asn
 1075 1080 1085
 Glu Gln Arg Trp Arg Trp Ile Phe Arg Ser Val Ile Tyr Glu Pro Tyr
 1090 1095 1100
 Leu Ala Met Phe Gly Gln Val Pro Ser Asp Val Asp Gly Thr Thr Tyr
 1105 1110 1115 1120
 Asp Phe Ala His Cys Thr Phe Thr Gly Asn Glu Ser Lys Pro Leu Cys
 1125 1130 1135
 Val Glu Leu Asp Glu His Asn Leu Pro Arg Phe Pro Glu Trp Ile Thr
 1140 1145 1150
 Ile Pro Leu Val Cys Ile Tyr Met Leu Ser Thr Asn Ile Leu Leu Val
 1155 1160 1165
 Asn Leu Leu Val Ala Met Phe Gly Cys Val Ala Gly Gly Leu Val Gln
 1170 1175 1180
 Val Leu Asp Phe Gly Thr Glu Asn Asn Leu Lys Val Ser Gln Lys Gln
 1185 1190 1195 1200
 Lys Gln Ala Arg Glu Leu Thr Ala Lys Pro Lys Tyr Thr Leu Ala Ala
 1205 1210 1215
 Ala Gly Phe Arg Arg Trp Thr Ser Ala Val Thr Ala Cys Leu Gln Pro
 1220 1225 1230
 Ala Arg Cys Leu Pro Gly Thr Gly Arg Gln Gly His Lys Ile Ser Leu
 1235 1240 1245
 Glu Met His Lys Gly Lys Ile Ala Glu Phe Ser Gln Gly Gln His Gln
 1250 1255 1260
 Met Ala Thr Gly Cys Gln Gly Asp Phe Lys Asn His Leu Arg Trp Gly
 1265 1270 1275 1280
 Gly Tyr Thr Val Gly Thr Val Gln Glu Asn Asn Asp Gln Val Trp Lys
 1285 1290 1295

Phe Gln Arg Tyr Phe Leu Val Gln Glu Tyr Cys Ser Arg Leu Asn Ile
 1300 1305 1310
 Pro Phe Pro Phe Ile Val Phe Ala Tyr Phe Tyr Met Val Val Lys Lys
 1315 1320 1325
 Cys Phe Lys Cys Cys Cys Lys Glu Lys Asn Met Glu Ser Ser Val Cys
 1330 1335 1340
 Ser Val Glu Ala Gly Glu Asp Ala Tyr Asn Tyr Arg Glu His Lys Glu
 1345 1350 1355 1360
 Gly Ser Lys Glu Leu Phe Gly Ser Gln Cys Ala Leu Met Leu Val Phe
 1365 1370 1375
 Ala Ala Thr Leu Ile Arg Cys Leu Phe Tyr Leu Glu Gly Ile Gly Asn
 1380 1385 1390

Ala

<210> 3
 <211> 651
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PBH1 peptide
 sequence

<400> 3
 Val Cys Lys Cys Gly Tyr Ala Gln Ser Gln His Met Glu Gly Thr Gln
 1 5 10 15
 Ile Asn Gln Ser Glu Lys Trp Asn Tyr Lys Lys His Thr Lys Glu Phe
 20 25 30
 Pro Thr Asp Ala Phe Gly Asp Ile Gln Phe Glu Thr Leu Gly Lys Lys
 35 40 45
 Gly Lys Tyr Ile Arg Leu Ser Cys Asp Thr Asp Ala Glu Ile Leu Tyr
 50 55 60
 Glu Leu Leu Thr Gln His Trp His Leu Lys Thr Pro Asn Leu Val Ile
 65 70 75 80
 Ser Val Thr Gly Gly Ala Lys Asn Phe Ala Leu Lys Pro Arg Met Arg
 85 90 95
 Lys Ile Phe Ser Arg Leu Ile Tyr Ile Ala Gln Ser Lys Gly Ala Trp
 100 105 110
 Ile Leu Thr Gly Gly Thr His Tyr Gly Leu Met Lys Tyr Ile Gly Glu
 115 120 125
 Val Val Arg Asp Asn Thr Ile Ser Arg Ser Ser Glu Glu Asn Ile Val
 130 135 140
 Ala Ile Gly Ile Ala Ala Trp Gly Met Val Ser Asn Arg Asp Thr Leu
 145 150 155 160

Ile	Arg	Asn	Cys	Asp	Ala	Glu	Gly	Tyr	Phe	Leu	Ala	Gln	Tyr	Leu	Met	
				165					170					175		
Asp	Asp	Phe	Thr	Arg	Asp	Pro	Leu	Tyr	Ile	Leu	Asp	Asn	Asn	His	Thr	
			180					185					190			
His	Leu	Leu	Leu	Val	Asp	Asn	Gly	Cys	His	Gly	His	Pro	Thr	Val	Glu	
		195					200					205				
Ala	Lys	Leu	Arg	Asn	Gln	Leu	Glu	Lys	Tyr	Ile	Ser	Glu	Arg	Thr	Ile	
	210					215					220					
Gln	Asp	Ser	Asn	Tyr	Gly	Gly	Lys	Ile	Pro	Ile	Val	Cys	Phe	Ala	Gln	
225					230					235					240	
Gly	Gly	Gly	Lys	Glu	Thr	Leu	Lys	Ala	Ile	Asn	Thr	Ser	Ile	Lys	Asn	
				245					250					255		
Lys	Ile	Pro	Cys	Val	Val	Val	Glu	Gly	Ser	Gly	Gln	Ile	Ala	Asp	Val	
			260					265					270			
Ile	Ala	Ser	Leu	Val	Glu	Val	Glu	Asp	Ala	Leu	Thr	Ser	Ser	Ala	Val	
		275					280					285				
Lys	Glu	Lys	Leu	Val	Arg	Phe	Leu	Pro	Arg	Thr	Val	Ser	Arg	Leu	Pro	
	290					295					300					
Glu	Glu	Glu	Thr	Glu	Ser	Trp	Ile	Lys	Trp	Leu	Lys	Glu	Ile	Leu	Glu	
305					310					315					320	
Cys	Ser	His	Leu	Leu	Thr	Val	Ile	Lys	Met	Glu	Glu	Ala	Gly	Asp	Glu	
				325					330					335		
Ile	Val	Ser	Asn	Ala	Ile	Ser	Tyr	Ala	Leu	Tyr	Lys	Ala	Phe	Ser	Thr	
			340					345					350			
Ser	Glu	Gln	Asp	Lys	Asp	Asn	Trp	Asn	Gly	Gln	Leu	Lys	Leu	Leu	Leu	
		355					360					365				
Glu	Trp	Asn	Gln	Leu	Asp	Leu	Ala	Asn	Asp	Glu	Ile	Phe	Thr	Asn	Asp	
	370					375					380					
Arg	Arg	Trp	Glu	Lys	Ser	Lys	Pro	Arg	Leu	Arg	Asp	Thr	Ile	Ile	Gln	
385					390					395					400	
Val	Thr	Trp	Leu	Glu	Asn	Gly	Arg	Ile	Lys	Val	Glu	Ser	Lys	Asp	Val	
				405					410					415		
Thr	Asp	Gly	Lys	Ala	Ser	Ser	His	Met	Leu	Val	Val	Leu	Lys	Ser	Ala	
			420					425					430			
Asp	Leu	Gln	Glu	Val	Met	Phe	Thr	Ala	Leu	Ile	Lys	Asp	Arg	Pro	Lys	
		435					440					445				
Phe	Val	Arg	Leu	Phe	Leu	Glu	Asn	Gly	Leu	Asn	Leu	Arg	Lys	Phe	Leu	
	450					455					460					
Thr	His	Asp	Val	Leu	Thr	Glu	Leu	Phe	Ser	Asn	His	Phe	Ser	Thr	Leu	
465					470					475					480	

Val Tyr Arg Asn Leu Gln Ile Ala Lys Asn Ser Tyr Asn Asp Ala Leu
 485 490 495
 Leu Thr Phe Val Trp Lys Leu Val Ala Asn Phe Arg Arg Gly Phe Arg
 500 505 510
 Lys Glu Asp Arg Asn Gly Arg Asp Glu Met Asp Ile Glu Leu His Asp
 515 520 525
 Val Ser Pro Ile Thr Arg His Pro Leu Gln Ala Leu Phe Ile Trp Ala
 530 535 540
 Ile Leu Gln Asn Lys Lys Glu Leu Ser Lys Val Ile Trp Glu Gln Thr
 545 550 555 560
 Arg Gly Cys Thr Leu Ala Ala Leu Gly Ala Ser Lys Leu Leu Lys Thr
 565 570 575
 Leu Ala Lys Val Lys Asn Asp Ile Asn Ala Ala Gly Glu Ser Glu Glu
 580 585 590
 Leu Ala Asn Glu Tyr Glu Thr Arg Ala Val Glu Leu Phe Thr Glu Cys
 595 600 605
 Tyr Ser Ser Asp Glu Asp Leu Ala Glu Gln Leu Leu Val Tyr Ser Cys
 610 615 620
 Glu Ala Trp Gly Gly Ser Asn Cys Leu Glu Leu Ala Val Glu Ala Thr
 625 630 635 640
 Asp Gln His Phe Ile Ala Gln Pro Gly Val Gln
 645 650

<210> 4
 <211> 649
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:transient
 receptor potential-related channel 7 (TRPC7)
 peptide sequence

<400> 4
 Val Cys Gln Cys Gly Tyr Thr His Glu Gln His Leu Glu Glu Ala Thr
 1 5 10 15
 Lys Pro His Thr Phe Gln Gly Thr Gln Trp Asp Pro Lys Lys His Val
 20 25 30
 Gln Glu Met Pro Thr Asp Ala Phe Gly Asp Ile Val Phe Thr Gly Leu
 35 40 45
 Ser Gln Lys Val Lys Lys Tyr Val Arg Val Ser Gln Asp Thr Pro Ser
 50 55 60
 Ser Val Ile Tyr His Leu Met Thr Gln His Trp Gly Leu Asp Val Pro
 65 70 75 80

Asn	Leu	Leu	Ile	Ser	Val	Thr	Gly	Gly	Ala	Lys	Asn	Phe	Asn	Met	Lys	85	90	95
Pro	Arg	Leu	Lys	Ser	Ile	Phe	Arg	Arg	Gly	Leu	Val	Lys	Val	Ala	Gln	100	105	110
Thr	Thr	Gly	Ala	Trp	Ile	Ile	Thr	Gly	Gly	Ser	His	Thr	Gly	Val	Met	115	120	125
Lys	Gln	Val	Gly	Glu	Ala	Val	Arg	Asp	Phe	Ser	Leu	Ser	Ser	Ser	Tyr	130	135	140
Lys	Glu	Gly	Glu	Leu	Ile	Thr	Ile	Gly	Val	Ala	Thr	Trp	Gly	Thr	Val	145	150	155
His	Arg	Arg	Glu	Gly	Leu	Ile	His	Pro	Thr	Gly	Ser	Phe	Pro	Ala	Glu	165	170	175
Tyr	Ile	Leu	Asp	Glu	Asp	Gly	Gln	Gly	Asn	Leu	Thr	Cys	Leu	Asp	Ser	180	185	190
Asn	His	Ser	His	Phe	Ile	Leu	Val	Asp	Asp	Gly	Thr	His	Gly	Gln	Tyr	195	200	205
Gly	Val	Glu	Ile	Pro	Leu	Arg	Thr	Arg	Leu	Glu	Lys	Phe	Ile	Ser	Glu	210	215	220
Gln	Thr	Lys	Glu	Arg	Gly	Gly	Val	Ala	Ile	Lys	Ile	Pro	Ile	Val	Cys	225	230	235
Val	Val	Leu	Glu	Gly	Gly	Pro	Gly	Thr	Leu	His	Thr	Ile	Asp	Asn	Ala	245	250	255
Thr	Thr	Asn	Gly	Thr	Pro	Cys	Val	Val	Val	Glu	Gly	Ser	Gly	Arg	Val	260	265	270
Ala	Asp	Val	Ile	Ala	Gln	Val	Ala	Asn	Leu	Pro	Val	Ser	Asp	Ile	Thr	275	280	285
Ile	Ser	Leu	Ile	Gln	Gln	Lys	Leu	Ser	Val	Phe	Phe	Gln	Glu	Met	Phe	290	295	300
Glu	Thr	Phe	Thr	Glu	Ser	Arg	Ile	Val	Glu	Trp	Thr	Lys	Lys	Ile	Gln	305	310	315
Asp	Ile	Val	Arg	Arg	Arg	Gln	Leu	Leu	Thr	Val	Phe	Arg	Glu	Gly	Lys	325	330	335
Asp	Gly	Gln	Gln	Asp	Val	Asp	Val	Ala	Ile	Leu	Gln	Ala	Leu	Leu	Lys	340	345	350
Ala	Ser	Arg	Ser	Gln	Asp	His	Phe	Gly	His	Glu	Asn	Trp	Asp	His	Gln	355	360	365
Leu	Lys	Leu	Ala	Val	Ala	Trp	Asn	Arg	Val	Asp	Ile	Ala	Arg	Ser	Glu	370	375	380
Ile	Phe	Met	Asp	Glu	Trp	Gln	Trp	Lys	Pro	Ser	Asp	Leu	His	Pro	Thr	385	390	395

<210> 6
 <211> 4
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:consensus
 peptide sequence from PBH1 and TRPC7 alignment

 <400> 6
 Thr Gln His Trp
 1

<210> 7
 <211> 10
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:consensus
 peptide sequence from PBH1 and TRPC7 alignment

 <400> 7
 Ile Ser Val Thr Gly Gly Ala Lys Asn Phe
 1 5 10

<210> 8
 <211> 4
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:consensus
 peptide sequence from PBH1 and TRPC7 alignment

 <400> 8
 Gly Ala Trp Ile
 1

<210> 9
 <211> 6
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:consensus
 peptide sequence from PBH1 and TRPC7 alignment

 <400> 9
 Lys Ile Pro Ile Val Cys
 1 5

<210> 10
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:consensus
peptide sequence from PBH1 and TRPC7 alignment

<400> 10
Pro Cys Val Val Val Glu Gly Ser Gly
1 5

<210> 11
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:consensus
peptide sequence from PBH1 and TRPC7 alignment

<400> 11
Ala Asp Val Ile Ala
1 5

<210> 12
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:consensus
peptide sequence from PBH1 and TRPC7 alignment

<400> 12
Leu Leu Thr Val
1

<210> 13
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:consensus
peptide sequence from PBH1 and TRPC7 alignment

<400> 13
Gln Leu Lys Leu
1

<210> 14
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:consensus
peptide sequence from PBH1 and TRPC7 alignment

<400> 14
Leu Phe Leu Glu Asn Gly
1 5

<210> 15
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:consensus
peptide sequence from PBH1 and TRPC7 alignment

<400> 15
Ile Trp Ala Ile
1

<210> 16
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:consensus
peptide sequence from PBH1 and TRPC7 alignment

<400> 16
Phe Thr Glu Cys Tyr
1 5

<210> 17
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:consensus
peptide sequence from PBH1 and TRPC7 alignment

<400> 17
Glu Ala Trp Gly
1

<210> 18
<211> 57
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PBH1 peptide
sequence

<400> 18
Ala Phe Phe Thr Ser Pro Phe Val Val Phe Ser Trp Asn Val Val Phe
1 5 10 15

Tyr Ile Ala Phe Leu Leu Leu Phe Ala Tyr Val Leu Leu Met Asp Phe
 20 25 30

His Ser Val Pro His Pro Pro Glu Leu Val Leu Tyr Ser Leu Val Phe
 35 40 45

Val Leu Phe Cys Asp Glu Val Arg Gln
 50 55

<210> 19
 <211> 57
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:transient
 receptor potential-related channel 7 (TRPC7)
 peptide sequence

<400> 19
 Ala Phe Phe Thr Ala Pro Val Val Val Phe His Leu Asn Ile Leu Ser
 1 5 10 15

Tyr Phe Ala Phe Leu Cys Leu Phe Ala Tyr Val Leu Met Val Asp Phe
 20 25 30

Gln Pro Val Pro Ser Trp Cys Glu Cys Ala Ile Tyr Leu Trp Leu Phe
 35 40 45

Ser Leu Val Cys Glu Glu Met Arg Gln
 50 55

<210> 20
 <211> 4
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:consensus
 peptide sequence from PBH1 and TRPC7 alignment

<400> 20
 Ala Phe Phe Thr
 1

<210> 21
 <211> 6
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:consensus
 peptide sequence from PBH1 and TRPC7 alignment

<400> 21
 Leu Phe Ala Tyr Val Leu
 1 5

```

<210> 22
<211> 225
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PBH1 peptide
sequence

<220>
<221> MOD_RES
<222> (77)..(82)
<223> Xaa = low complexity amino acid from BLASTP search

<400> 22
Tyr Phe Thr Asp Leu Trp Asn Val Met Asp Thr Leu Gly Leu Phe Tyr
 1             5             10             15

Phe Ile Ala Gly Ile Val Phe Arg Leu His Ser Ser Asn Lys Ser Ser
      20             25             30

Leu Tyr Ser Gly Arg Val Ile Phe Cys Leu Asp Tyr Ile Ile Phe Thr
      35             40             45

Leu Arg Leu Ile His Ile Phe Thr Val Ser Arg Asn Leu Gly Pro Lys
      50             55             60

Ile Ile Met Leu Gln Arg Met Thr Ser Ile Glu Met Xaa Xaa Xaa Xaa
      65             70             75             80

Xaa Xaa Ile Pro Thr Leu Arg Phe Phe Glu Phe Val Val Leu Ile Gln
      85             90             95

Ser Ile Ser Gly Thr Ser Ser His His Glu Val Met Leu Ser Asp Arg
      100            105            110

Cys Val Leu Leu Pro Val Pro Leu Cys Gly Val Asp Gly Gly Leu Cys
      115            120            125

Val Ala Arg Gln Gly Ile Leu Arg Gln Asn Glu Gln Arg Trp Arg Trp
      130            135            140

Ile Phe Arg Ser Val Ile Tyr Glu Pro Tyr Leu Ala Met Phe Gly Gln
      145            150            155            160

Val Pro Ser Asp Val Asp Gly Thr Thr Tyr Asp Phe Ala His Cys Thr
      165            170            175

Phe Thr Gly Asn Glu Ser Lys Pro Leu Cys Val Glu Leu Asp Glu His
      180            185            190

Asn Leu Pro Arg Phe Pro Glu Trp Ile Thr Ile Pro Leu Val Cys Ile
      195            200            205

Tyr Met Leu Ser Thr Asn Ile Leu Leu Val Asn Leu Leu Val Ala Met
      210            215            220

Phe
225

```


<210> 23
 <211> 186
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:transient
 receptor potential-related channel 7 (TRPC7)
 peptide sequence

<400> 23
 Tyr Phe Ser Asp Phe Trp Asn Lys Leu Asp Val Gly Ala Ile Leu Leu
 1 5 10 15
 Phe Val Ala Gly Leu Thr Cys Arg Leu Ile Pro Ala Thr Leu Tyr Pro
 20 25 30
 Gly Arg Val Ile Leu Ser Leu Asp Phe Ile Leu Phe Cys Leu Arg Leu
 35 40 45
 Met His Ile Phe Thr Ile Ser Lys Thr Leu Gly Pro Lys Ile Ile Ile
 50 55 60
 Val Lys Arg Met Met Lys Asp Val Phe Phe Phe Leu Phe Leu Leu Ala
 65 70 75 80
 Val Trp Val Val Ser Phe Gly Val Ala Lys Gln Ala Ile Leu Ile His
 85 90 95
 Asn Glu Arg Arg Val Asp Trp Leu Phe Arg Gly Ala Val Tyr His Ser
 100 105 110
 Tyr Leu Thr Ile Phe Gly Gln Ile Pro Gly Tyr Ile Asp Gly Val Asn
 115 120 125
 Phe Asn Pro Glu His Cys Ser Pro Asn Gly Thr Asp Pro Tyr Lys Pro
 130 135 140
 Lys Cys Pro Glu Ser Asp Ala Thr Gln Gln Arg Pro Ala Phe Pro Glu
 145 150 155 160
 Trp Leu Thr Val Leu Leu Leu Cys Leu Tyr Leu Leu Phe Thr Asn Ile
 165 170 175
 Leu Leu Leu Asn Leu Leu Ile Ala Met Phe
 180 185

<210> 24
 <211> 4
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:consensus
 peptide sequence from PBH1 and TRPC7 alignment

<400> 24
 Gly Arg Val Ile
 1

<210> 25
 <211> 4
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:consensus
 peptide sequence from PBH1 and TRPC7 alignment

 <400> 25
 His Ile Phe Thr
 1

<210> 26
 <211> 6
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:consensus
 peptide sequence from PBH1 and TRPC7 alignment

 <400> 26
 Leu Gly Pro Lys Ile Ile
 1 5

<210> 27
 <211> 4
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:consensus
 peptide sequence from PBH1 and TRPC7 alignment

 <400> 27
 Phe Pro Glu Trp
 1

<210> 28
 <211> 5
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:consensus
 peptide sequence from PBH1 and TRPC7 alignment

 <400> 28
 Thr Asn Ile Leu Leu
 1 5

<210> 29
 <211> 45
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PBH1 peptide
 sequence

<400> 29
 Tyr Thr Val Gly Thr Val Gln Glu Asn Asn Asp Gln Val Trp Lys Phe
 1 5 10 15
 Gln Arg Tyr Phe Leu Val Gln Glu Tyr Cys Ser Arg Leu Asn Ile Pro
 20 25 30
 Phe Pro Phe Ile Val Phe Ala Tyr Phe Tyr Met Val Val
 35 40 45

<210> 30
 <211> 45
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:transient
 receptor potential-related channel 7 (TRPC7)
 peptide sequence

<400> 30
 Tyr Thr Phe Gln Gln Val Gln Glu His Thr Asp Gln Ile Trp Lys Phe
 1 5 10 15
 Gln Arg His Asp Leu Ile Glu Glu Tyr His Gly Arg Pro Ala Ala Pro
 20 25 30
 Pro Pro Phe Ile Leu Leu Ser His Leu Gln Leu Phe Ile
 35 40 45

<210> 31
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:consensus
 peptide sequence for PBH1 and TRPC7 alignment

<400> 31
 Trp Lys Phe Gln Arg
 1 5

<210> 32
 <211> 2181
 <212> DNA
 <213> Homo sapiens

<220>
 <223> exons 1-15 of PBH1

<400> 32
 gccagcttct acgctgcctt caggacacag acgtgcccaa tcatggcttc ttggtgcttg 60
 attacagctc aagtctgggt caaaatgaag ggagatgtgg tgggcagccg cagccctcag 120

caacacaagc	ggagcacagg	aacacctcag	ggtcttccag	ttcccatctc	agaaggctca	180
atgaaatcct	tccttcctgt	ccacaccatc	gtgcttatca	gggagaatgt	gtgcaagtgt	240
ggctatgcc	agagccagca	catggaaggc	accagatca	accaaagtga	gaaatggaac	300
tacaagaaac	acaccaagga	atttcctacc	gacgcctttg	gggatatcca	gtttgagaca	360
ctggggaaga	aagggaagta	tatacgtctg	tcctgcgaca	cggacgcgga	aatcctttac	420
gagctgctga	cccagcactg	gcacctgaaa	acacccaacc	tggtcatttc	tgtgaccggg	480
ggcgccaaga	acttcgccct	gaagccgcgc	atgcgcaaga	tcttcagccg	gctcatctac	540
atcgcgcagt	ccaaaggtgc	ttggattctc	acgggaggca	cccattatgg	cctgatgaag	600
tacatcgggg	aggtggtgag	agataacacc	atcagcagga	gttcagagga	gaatattgtg	660
gccattggca	tagcagcttg	gggcatggtc	tccaaccggg	acaccctcat	caggaattgc	720
gatgctgagg	gctatttttt	agcccagtac	cttatggatg	acttcacaag	agatccactg	780
tatatcctgg	acaacaacca	cacacatttg	ctgctcgtgg	acaatggctg	tcattggacat	840
cccactgtcg	aagcaaagct	ccggaatcag	ctagagaagt	atatctctga	gcgcactatt	900
caagattcca	actatggtgg	caagatcccc	atttgtgtgt	ttgcccgaag	aggtggaaaa	960
gagactttga	aagccatcaa	tacctccatc	aaaaataaaa	ttccttgtgt	ggtggtggaa	1020
ggctcggggc	agatcgctga	tgtgatcgct	agcctgggtg	aggtggagga	tgccctgaca	1080
tcttctgccg	tcaaggagaa	gctggtgcgc	tttttaccct	gcacggtgtc	ccggtgcct	1140
gaggaggaga	ctgagagttg	gatcaaattg	ctcaaagaaa	ttctcgaatg	ttctcaccta	1200
ttaacagtta	ttaaaatgga	agaagctggg	gatgaaattg	tgagcaatgc	catctcctac	1260
gctctataca	aagccttcag	caccagttag	caagacaagg	ataactggaa	tgggcagctg	1320
aagcttctgc	tggagtggaa	ccagctggac	ttagccaatg	atgagatttt	caccaatgac	1380
cgccgatggg	agaagagcaa	accgaggctc	agagacacaa	taatccaggt	cacatggctg	1440
gaaaatggta	gaatcaaggt	tgagagcaaa	gatgtgactg	acggcaaagc	ctcttctcat	1500
atgctgggtg	ttctcaagtc	tgctgacctt	caagaagtca	tgtttacggc	tctcataaag	1560
gacagaccca	agtttgtccg	cctctttctg	gagaatggct	tgaacctacg	gaagtttctc	1620
acccatgatg	tcctcactga	actcttctcc	aaccacttca	gcacgcttgt	gtaccggaat	1680
ctgcagatcg	ccaagaattc	ctataatgat	gccctcctca	cgtttgtctg	gaaactgggt	1740
gcgaacttcc	gaagaggctt	ccggaaggaa	gacagaaatg	gccgggacga	gatggacata	1800
gaactccacg	acgtgtctcc	tattactcgg	cacccctcgc	aagctctctt	catctgggcc	1860
attcttcaga	ataagaagga	actctccaaa	gtcatttggg	agcagaccag	gggctgcact	1920
ctggcagccc	tgggagccag	caagcttctg	aagactctgg	ccaaagtga	gaacgacatc	1980
aatgctgctg	gggagtcgga	ggagctggct	aatgagtagc	agacccgggc	tggtgagctg	2040
ttcactgagt	gttacagcag	cgatgaagac	ttggcagaac	agctgctggg	ctattcctgt	2100
gaagcttggg	gtggaagcaa	ctgtctggag	ctggcggtgg	aggccacaga	ccagcatttc	2160
atcgcccagc	ctggggtcca	g				2181

<210> 33
 <211> 283
 <212> DNA
 <213> Homo sapiens

<220>
 <223> exon 16 of PBH1

<400> 33						
gaggggaggg	ctgtgcccgt	cccatgcttg	caaggatgct	gacgatgccc	ttatctctgg	60
gtccaggaag	aaacctgtcg	acaagcacia	gaagctgctt	tggtactatg	tggcgttctt	120
cacctcccc	ttcgtggtct	tctcctggaa	tgtggtcttc	tacatcgctt	tcctcctgct	180
gtttgcctac	gtgctgctca	tggatttcca	ttcgggtgcca	cacccccccg	agctggctct	240
gtactcgctg	gtctttgtcc	tcttctgtga	tgaagtga	cag		283

<210> 34
 <211> 1761
 <212> DNA
 <213> Homo sapiens

<220>
 <223> exons 17-28 of PBH1

```

<400> 34
atggagcagg ggggtggcgct cgtggaggag gctcgggcag cacaggagcc cactgagggg 60
gtgggagggt caggcatggt gggctgcagg tcccagagcc tgccccacgg gaaggcagct 120
acggcccggc ccggttcccg ctcacgccac tccttccaca ctccctgca agctgagggg 180
gccagctctg gccttgccca gccagaaaag gggctcccac agtgacagcg tgggctgaag 240
ggctcctcaa gtgccgcaa agtgggagcc caggcagagg aggtgccgag agcaagcgag 300
ggctgtgagg actgccagca cgctgtcacc tctcagaagc gtaagggact ggctgatgtc 360
ttatcacgga ctgggaacaa ctgggacagt gtctgccccca caagtgggtg gtacgtaaat 420
gggggtgaatt attttactga cctgtggaat gtgatggaca cgctgggggt tttttacttc 480
atagcaggaa ttgtatttcg gctccactct tctaataaaa gctctttgta ttctggacga 540
gtcattttct gtctggacta cattattttc actctaagat tgatccacat ttttactgta 600
agcagaaact taggacccaa gattataatg ctgcagagga tgacgagcat tgagatgagc 660
tcacttgga gctccattcc aacactgagg ttctttgagt ttgtggtttt aattcaaagc 720
atttctggga catccagtca tcatgaagtc atgctatctg atcgatgtgt tcttcttctc 780
gttctctctt gcggtgtgga tgggtggcct tgcgtggcca ggcaagggat ccttaggcag 840
aatgagcagc gctggagggt gatattccgt tcggtcatct acgagcccta cctggccatg 900
ttcgccagg tgcccagtga cgtggatggt accacgtatg actttgcca ctgcaccttc 960
actgggaatg agtccaagcc actgtgtgtg gagctggatg agcacaacct gccccgggtc 1020
cccagagtga tcaccatccc cctggtgtgc atctacatgt tatccaccaa catcctgctg 1080
gtcaacctgc tggtcgccat gtttgggtgt gtagccgggt ggctagtcca ggttcttgac 1140
tttgggacag aaaataattt gaaagtgagt caaaagcaaa agcaagcaag agagttgact 1200
gcaaagccaa agtacactct agcagccgct ggtttcagga gatggacctc agctgtcact 1260
gcatgtctcc agccagctag gtgtttgccca gggacaggac gccaaagggca caagatatcg 1320
ctggagatgc acaaagggaa aattgcagaa ttctctcagg gacaacacca gatggccact 1380
ggttgtcaag gagactttaa gaaccatctc agatggggcg gctacacggt gggcaccgtc 1440
caggagaaca atgaccaggt ctggaagtcc cagaggtact tcttggtgca ggagtactgc 1500
agccgcctca atatccctt ccccttcac gtcttcgctt acttctacat ggtggtgaag 1560
aagtgttca agtgttgctg caaggagaaa aacatggagt cttctgtctg ctctgtggag 1620
gcagggtgaag atgcttacia ttatagggaa cataaggaag gctcaaaaaga gctttttggg 1680
agccagtgtg ccttgatgct agtctttgct gccactctga ttcgttgctt gttttatttg 1740
gagggcattg gaaatgcgtg a 1761

```

```

<210> 35
<211> 713
<212> PRT
<213> Homo sapiens

```

```

<220>
<223> exons 1-15 of PBH1

```

```

<400> 35
Met Ala Ser Trp Cys Leu Ile Thr Ala Gln Val Trp Val Lys Met Lys
  1             5             10             15

Gly Asp Val Val Gly Ser Arg Ser Pro Gln Gln His Lys Arg Ser Thr
      20             25             30

Gly Thr Pro Gln Gly Leu Pro Val Pro Ile Ser Glu Gly Ser Met Lys
      35             40             45

Ser Phe Leu Pro Val His Thr Ile Val Leu Ile Arg Glu Asn Val Cys
      50             55             60

Lys Cys Gly Tyr Ala Gln Ser Gln His Met Glu Gly Thr Gln Ile Asn
      65             70             75             80

Gln Ser Glu Lys Trp Asn Tyr Lys Lys His Thr Lys Glu Phe Pro Thr
      85             90             95

```

Asp	Ala	Phe	Gly	Asp	Ile	Gln	Phe	Glu	Thr	Leu	Gly	Lys	Lys	Gly	Lys	100	105	110	
Tyr	Ile	Arg	Leu	Ser	Cys	Asp	Thr	Asp	Ala	Glu	Ile	Leu	Tyr	Glu	Leu	115	120	125	
Leu	Thr	Gln	His	Trp	His	Leu	Lys	Thr	Pro	Asn	Leu	Val	Ile	Ser	Val	130	135	140	
Thr	Gly	Gly	Ala	Lys	Asn	Phe	Ala	Leu	Lys	Pro	Arg	Met	Arg	Lys	Ile	145	150	155	160
Phe	Ser	Arg	Leu	Ile	Tyr	Ile	Ala	Gln	Ser	Lys	Gly	Ala	Trp	Ile	Leu	165	170	175	
Thr	Gly	Gly	Thr	His	Tyr	Gly	Leu	Met	Lys	Tyr	Ile	Gly	Glu	Val	Val	180	185	190	
Arg	Asp	Asn	Thr	Ile	Ser	Arg	Ser	Ser	Glu	Glu	Asn	Ile	Val	Ala	Ile	195	200	205	
Gly	Ile	Ala	Ala	Trp	Gly	Met	Val	Ser	Asn	Arg	Asp	Thr	Leu	Ile	Arg	210	215	220	
Asn	Cys	Asp	Ala	Glu	Gly	Tyr	Phe	Leu	Ala	Gln	Tyr	Leu	Met	Asp	Asp	225	230	235	240
Phe	Thr	Arg	Asp	Pro	Leu	Tyr	Ile	Leu	Asp	Asn	Asn	His	Thr	His	Leu	245	250	255	
Leu	Leu	Val	Asp	Asn	Gly	Cys	His	Gly	His	Pro	Thr	Val	Glu	Ala	Lys	260	265	270	
Leu	Arg	Asn	Gln	Leu	Glu	Lys	Tyr	Ile	Ser	Glu	Arg	Thr	Ile	Gln	Asp	275	280	285	
Ser	Asn	Tyr	Gly	Gly	Lys	Ile	Pro	Ile	Val	Cys	Phe	Ala	Gln	Gly	Gly	290	295	300	
Gly	Lys	Glu	Thr	Leu	Lys	Ala	Ile	Asn	Thr	Ser	Ile	Lys	Asn	Lys	Ile	305	310	315	320
Pro	Cys	Val	Val	Val	Glu	Gly	Ser	Gly	Gln	Ile	Ala	Asp	Val	Ile	Ala	325	330	335	
Ser	Leu	Val	Glu	Val	Glu	Asp	Ala	Leu	Thr	Ser	Ser	Ala	Val	Lys	Glu	340	345	350	
Lys	Leu	Val	Arg	Phe	Leu	Pro	Arg	Thr	Val	Ser	Arg	Leu	Pro	Glu	Glu	355	360	365	
Glu	Thr	Glu	Ser	Trp	Ile	Lys	Trp	Leu	Lys	Glu	Ile	Leu	Glu	Cys	Ser	370	375	380	
His	Leu	Leu	Thr	Val	Ile	Lys	Met	Glu	Glu	Ala	Gly	Asp	Glu	Ile	Val	385	390	395	400
Ser	Asn	Ala	Ile	Ser	Tyr	Ala	Leu	Tyr	Lys	Ala	Phe	Ser	Thr	Ser	Glu	405	410	415	

Gln Asp Lys Asp Asn Trp Asn Gly Gln Leu Lys Leu Leu Leu Glu Trp
 420 425 430
 Asn Gln Leu Asp Leu Ala Asn Asp Glu Ile Phe Thr Asn Asp Arg Arg
 435 440 445
 Trp Glu Lys Ser Lys Pro Arg Leu Arg Asp Thr Ile Ile Gln Val Thr
 450 455 460
 Trp Leu Glu Asn Gly Arg Ile Lys Val Glu Ser Lys Asp Val Thr Asp
 465 470 475 480
 Gly Lys Ala Ser Ser His Met Leu Val Val Leu Lys Ser Ala Asp Leu
 485 490 495
 Gln Glu Val Met Phe Thr Ala Leu Ile Lys Asp Arg Pro Lys Phe Val
 500 505 510
 Arg Leu Phe Leu Glu Asn Gly Leu Asn Leu Arg Lys Phe Leu Thr His
 515 520 525
 Asp Val Leu Thr Glu Leu Phe Ser Asn His Phe Ser Thr Leu Val Tyr
 530 535 540
 Arg Asn Leu Gln Ile Ala Lys Asn Ser Tyr Asn Asp Ala Leu Leu Thr
 545 550 555 560
 Phe Val Trp Lys Leu Val Ala Asn Phe Arg Arg Gly Phe Arg Lys Glu
 565 570 575
 Asp Arg Asn Gly Arg Asp Glu Met Asp Ile Glu Leu His Asp Val Ser
 580 585 590
 Pro Ile Thr Arg His Pro Leu Gln Ala Leu Phe Ile Trp Ala Ile Leu
 595 600 605
 Gln Asn Lys Lys Glu Leu Ser Lys Val Ile Trp Glu Gln Thr Arg Gly
 610 615 620
 Cys Thr Leu Ala Ala Leu Gly Ala Ser Lys Leu Leu Lys Thr Leu Ala
 625 630 635 640
 Lys Val Lys Asn Asp Ile Asn Ala Ala Gly Glu Ser Glu Glu Leu Ala
 645 650 655
 Asn Glu Tyr Glu Thr Arg Ala Val Glu Leu Phe Thr Glu Cys Tyr Ser
 660 665 670
 Ser Asp Glu Asp Leu Ala Glu Gln Leu Leu Val Tyr Ser Cys Glu Ala
 675 680 685
 Trp Gly Gly Ser Asn Cys Leu Glu Leu Ala Val Glu Ala Thr Asp Gln
 690 695 700
 His Phe Ile Ala Gln Pro Gly Val Gln
 705 710

<210> 36
 <211> 94
 <212> PRT
 <213> Homo sapiens

<220>
 <223> exon 16 of PBH1

<400> 36
 Arg Gly Gly Leu Cys Pro Ser His Ala Cys Lys Asp Ala Asp Asp Ala
 1 5 10 15
 Leu Ile Ser Gly Ser Arg Lys Lys Pro Val Asp Lys His Lys Lys Leu
 20 25 30
 Leu Trp Tyr Tyr Val Ala Phe Phe Thr Ser Pro Phe Val Val Phe Ser
 35 40 45
 Trp Asn Val Val Phe Tyr Ile Ala Phe Leu Leu Leu Phe Ala Tyr Val
 50 55 60
 Leu Leu Met Asp Phe His Ser Val Pro His Pro Pro Glu Leu Val Leu
 65 70 75 80
 Tyr Ser Leu Val Phe Val Leu Phe Cys Asp Glu Val Arg Gln
 85 90

<210> 37
 <211> 586
 <212> PRT
 <213> Homo sapiens

<220>
 <223> exons 17-28 of PBH1

<400> 37
 Met Glu Gln Gly Val Ala Leu Val Glu Glu Ala Arg Ala Ala Gln Glu
 1 5 10 15
 Pro Thr Glu Gly Val Gly Gly Ser Gly Met Val Gly Cys Arg Ser Arg
 20 25 30
 Ala Leu Pro His Gly Lys Ala Ala Thr Ala Arg Pro Gly Ser Arg Ser
 35 40 45
 Arg His Ser Phe His Thr Ser Leu Gln Ala Glu Gly Ala Ser Ser Gly
 50 55 60
 Leu Gly Gln Pro Arg Lys Gly Leu Pro Gln Cys Ser Gly Gly Leu Lys
 65 70 75 80
 Gly Ser Ser Ser Ala Ala Lys Val Gly Ala Gln Ala Glu Glu Val Pro
 85 90 95
 Arg Ala Ser Glu Gly Cys Glu Asp Cys Gln His Ala Val Thr Ser Gln
 100 105 110
 Lys Arg Lys Gly Leu Ala Asp Val Leu Ser Arg Thr Gly Asn Asn Trp
 115 120 125

Ala Glu Phe Ser Gln Gly Gln His Gln Met Ala Thr Gly Cys Gln Gly
 450 455 460
 Asp Phe Lys Asn His Leu Arg Trp Gly Gly Tyr Thr Val Gly Thr Val
 465 470 475 480
 Gln Glu Asn Asn Asp Gln Val Trp Lys Phe Gln Arg Tyr Phe Leu Val
 485 490 495
 Gln Glu Tyr Cys Ser Arg Leu Asn Ile Pro Phe Pro Phe Ile Val Phe
 500 505 510
 Ala Tyr Phe Tyr Met Val Val Lys Lys Cys Phe Lys Cys Cys Cys Lys
 515 520 525
 Glu Lys Asn Met Glu Ser Ser Val Cys Ser Val Glu Ala Gly Glu Asp
 530 535 540
 Ala Tyr Asn Tyr Arg Glu His Lys Glu Gly Ser Lys Glu Leu Phe Gly
 545 550 555 560
 Ser Gln Cys Ala Leu Met Leu Val Phe Ala Ala Thr Leu Ile Arg Cys
 565 570 575
 Leu Phe Tyr Leu Glu Gly Ile Gly Asn Ala
 580 585

<210> 38
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:cytokine
 receptor transmembrane protein extracellular
 domain conserved motif

<220>
 <221> MOD_RES
 <222> (3)
 <223> Xaa = any amino acid

<400> 38
 Trp Ser Xaa Trp Ser
 1 5

<210> 39
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:T7-(dT)-24
 primer

<400> 39
 tttttttttt tttttttttt tttt

<210> 40
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:amino acids
 168-180 from PBH1 exons 17-28, extracellular
 region used to generate therapeutic antibodies

<400> 40
 Leu His Ser Ser Asn Lys Ser Ser Leu Tyr Ser Gly Arg
 1 5 10

<210> 41
 <211> 68
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:amino acids
 274-342 from PBH1 exons 17-28, extracellular
 region used to generate therapeutic antibodies

<400> 41
 Arg Gln Gly Ile Leu Arg Gln Asn Glu Gln Arg Trp Arg Trp Ile Phe
 1 5 10 15
 Arg Ser Val Ile Tyr Glu Pro Tyr Leu Ala Met Phe Gly Gln Val Pro
 20 25 30
 Ser Asp Val Asp Gly Thr Thr Tyr Asp Phe Ala His Cys Thr Phe Thr
 35 40 45
 Gly Asn Glu Ser Lys Pro Leu Cys Val Glu Leu Asp Glu His Asn Leu
 50 55 60
 Pro Arg Phe Pro
 65

<210> 42
 <211> 41
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:amino acids
 520-560 from PBH1 exons 17-28, extracellular
 region used to generate therapeutic antibodies

<400> 42
 Lys Lys Cys Phe Lys Cys Cys Cys Lys Glu Lys Asn Met Glu Ser Ser
 1 5 10 15
 Val Cys Ser Val Glu Ala Gly Glu Asp Ala Tyr Asn Tyr Arg Glu His
 20 25 30
 Lys Glu Gly Ser Lys Glu Leu Phe Gly
 35 40